Financial Performance - For the three months ended September 30, 2025, net income attributable to common stockholders was $282, compared to a loss of $1,970 for the same period in 2024[165]. - FFO for the three months ended September 30, 2025, was $4,217, an increase of 90% from $2,216 in 2024[165]. - AFFO for the three months ended September 30, 2025, was $4,511, up from $3,702 in 2024, representing a 22% increase[165]. - The rental revenue for the nine months ended September 30, 2025, remained constant at $34.8 million compared to 2024[178]. - General and administrative expenses decreased by 10% to $4.6 million for the nine months ended September 30, 2025, down from $5.1 million in 2024[179]. - Other expenses decreased to $3.8 million for the three months ended September 30, 2025, down from $5.9 million in 2024, primarily due to reduced losses on interest rate derivatives[177]. - Depreciation and amortization expense decreased by $1.0 million, or 8%, to $11.4 million for the nine months ended September 30, 2025, primarily due to the classification of a property as held for sale[181]. - The gain on sale of real estate investments was $0.1 million for the nine months ended September 30, 2025, compared to $3.4 million in 2024[184]. - Other expenses decreased to $11.5 million for the nine months ended September 30, 2025, from $11.8 million in 2024, primarily due to the absence of losses on interest rate derivatives[185]. Real Estate Investments - As of September 30, 2025, the net book value of the company's real estate investments was $462.9 million[124]. - The annual base rent (ABR) totaled $38.9 million, with 39 industrial properties representing approximately 82% of the portfolio by ABR[129]. - The occupancy rate of the portfolio was 96%, with a weighted average remaining lease term (WALT) of approximately 14.2 years[129]. - The company transformed its portfolio, increasing the percentage of ABR from industrial properties to 82% by September 30, 2025, up from 41% in December 2021[167]. - The weighted average lease term (WALT) increased to 14.2 years as of September 30, 2025, compared to 6.1 years in December 2021[167]. - The company acquired an industrial property for $6.1 million, representing an initial cap rate of 8.00%[150]. - The company owned 43 operating properties as of September 30, 2025, with acquisitions made in March 2025 and July 2024[170]. Debt and Liquidity - The company has a leverage ratio of 47.6% as of December 31, 2024, and 100% of consolidated indebtedness has a weighted average fixed interest rate of 4.27%[128][133]. - The Credit Facility includes a $280.0 million line of credit, with a $30.0 million revolving line and a $250.0 million term loan[140]. - The interest rate on the Revolver was 6.10% as of October 31, 2025, with a leverage ratio of 47.7%[142]. - The company expects to have adequate liquidity to meet cash requirements for the next 12 months and beyond[137]. - As of September 30, 2025, the outstanding principal balance of the Term Loan was $250.0 million, with a leverage ratio of 47.6%[143]. Stock and Dividends - The company sold 79,415 shares of Class C Common Stock in the ATM Offering during the three months ended September 30, 2025, generating proceeds of $1.2 million[138]. - The company repurchased Series A Preferred Stock for $6.5 million during the nine months ended September 30, 2025[158]. - Preferred dividends declared for the first three quarters of 2025 totaled $0.8 million each, paid on April 15, July 15, and October 15, 2025[186]. - The company repurchased 275,000 shares of Series A Preferred Stock for a total of $6.5 million at an average cost of $23.74 per share, representing 13.8% of shares issued[190]. - The company intends to maintain its REIT status, which requires distributing at least 90% of its annual taxable income[191]. - The distribution rate for common stock is determined by the board of directors and has not been pre-established[187]. Expenses and Obligations - The company had obligations to reimburse $2.2 million for future tenant improvements expected to be incurred by tenants as of September 30, 2025[153]. - The company has identified approximately $0.5 million of capital expenditures expected to be completed in the next 12 months[154]. - The company paid aggregate premiums of $4.2 million during the nine months ended September 30, 2025, to buy down the swaps fixed rate[157]. - Stock compensation expense for the nine months ended September 30, 2025, was $2.1 million, a 38% increase from $1.5 million in 2024[180]. Compliance and Accounting - The company was in compliance with all financial loan covenants as of September 30, 2025[148]. - The company has not made significant changes to its accounting policies during the three months ended September 30, 2025[193]. Impairments - An impairment charge of $4.0 million was recorded for property and equipment in Saint Paul, Minnesota, during the nine months ended September 30, 2025, with no impairment charges in the same period of 2024[183].

Financial Position - As of September 30, 2025, Lunai Bioworks Inc. reported cash and cash equivalents of $624,808 and an accumulated deficit of $507,643,549 [142]. - The company has a working capital deficit of $18,922,114, raising substantial doubt about its ability to continue as a going concern for one year after the financial statements are issued [142]. - Total assets decreased to $6,960,663 as of September 30, 2025, from $8,230,840 as of June 30, 2025 [158]. - Total liabilities decreased to $20,001,437 as of September 30, 2025, from $29,580,681 as of June 30, 2025 [159]. - The company incurred net cash used in operating activities of $1,349,110 for the three months ended September 30, 2025, compared to $2,016,328 in 2024 [160]. - Cash provided by financing activities was $1,343,357 for the three months ended September 30, 2025, compared to $2,029,183 in 2024 [162]. - The company has never generated revenues and does not anticipate earning any until its therapies or products are approved for marketing and sale [148]. Operational Performance - Operating expenses for the three months ended September 30, 2025, were $3,308,360, a decrease of $50,030,194 or approximately 94% compared to $53,338,554 in 2024 [149]. - General and administrative expenses decreased by $2,890,735 or approximately 55%, from $5,301,251 in 2024 to $2,410,516 in 2025 [150]. - Research and development expenses dropped by $365,782 or approximately 94%, from $390,189 in 2024 to $24,407 in 2025 [151]. - The company reported a net income of $2,819,021 for the three months ended September 30, 2025, compared to a net loss of $44,212,036 in 2024, representing a decrease in net loss of $47,031,057 or approximately 106% [153]. - As of September 30, 2025, the company had $624,808 in cash, an increase of 574% compared to $92,700 as of June 30, 2025 [157]. Business Development - Renovaro Biosciences aims to develop advanced allogeneic cell and gene therapies for long-term cancer remission and serious infectious diseases, pending necessary funding [117]. - The allogeneic cell therapy platform has completed the pre-IND and IND-enabling phase, focusing on long-term remission of solid tumors, particularly pancreatic cancer [122]. - BioSymetrics integrates multimodal data sources to advance biomarker discovery and therapeutic development, collaborating with pharmaceutical companies and healthcare providers [127][128]. - BioSymetrics has developed a proprietary knowledge graph, the Phenograph, mapping 5,856 diseases and 16,676 human genes to enhance drug target identification [131]. - The company screened 1,400 compounds in a zebrafish model, identifying a hit compound that showed efficacy in a mouse seizure model, progressing as a potential therapeutic [133]. - BioSymetrics intends to expand its platform across biopharmaceutical and healthcare markets, focusing on compliance with healthcare data privacy regulations [137]. Corporate Changes - GediCube, B.V., acquired in February 2024, filed for bankruptcy and will no longer be reported on starting in Q2 2026 [116]. - The company has incurred substantial recurring losses and is dependent on additional financing to fund operations [142].

Financial Position - As of September 30, 2025, Lunai Bioworks Inc. reported cash and cash equivalents of $624,808 and an accumulated deficit of $507,643,549[142]. - The company has a working capital deficit of $18,922,114, raising substantial doubt about its ability to continue as a going concern for one year after the financial statements are issued[142]. - Total assets decreased to $6,960,663 as of September 30, 2025, from $8,230,840 as of June 30, 2025, primarily due to impairments[158]. - Total liabilities decreased to $20,001,437 as of September 30, 2025, from $29,580,681 as of June 30, 2025, mainly due to reductions in notes payable and accrued expenses[159]. - The company incurred net cash used in operating activities of $1,349,110 for the three months ended September 30, 2025, compared to $2,016,328 for the same period in 2024[160]. - Cash provided by financing activities was $1,343,357 for the three months ended September 30, 2025, compared to $2,029,183 in the same period of 2024[160]. Company Performance - The company reduced operating expenses for the three months ended September 30, 2025, to $3,308,360, a decrease of $50,030,194 or approximately 94% compared to $53,338,554 in the same period of 2024[149]. - General and administrative expenses decreased by $2,890,735 or approximately 55%, from $5,301,251 in Q3 2024 to $2,410,516 in Q3 2025[150]. - Research and development expenses fell by $365,782 or approximately 94%, from $390,189 in Q3 2024 to $24,407 in Q3 2025[151]. - The company reported a net income of $2,819,021 for the three months ended September 30, 2025, compared to a net loss of $44,212,036 in the same period of 2024, representing a decrease in net loss of $47,031,057 or approximately 106%[153]. - As of September 30, 2025, the company had $624,808 in cash, an increase of 574% compared to $92,700 in cash as of June 30, 2025[157]. Business Development - Renovaro Biosciences is developing allogeneic cell and gene therapies aimed at long-term cancer remission and treatment of serious infectious diseases like HIV[117]. - The allogeneic cell therapy platform has completed the pre-IND and IND-enabling phase, focusing on solid tumors such as pancreatic and triple negative breast cancers[122]. - BioSymetrics, acquired on April 8, 2025, integrates multimodal data sources to advance biomarker discovery and precision medicine[127]. - BioSymetrics has developed proprietary machine learning pipelines for analyzing complex datasets, enhancing pharmaceutical research and early disease detection[128]. - The Phenograph knowledge graph maps human genes and phenotypes to model systems, containing 5,856 diseases and 16,676 human genes[131]. - BioSymetrics screened 1,400 compounds in a zebrafish model, identifying a hit compound that showed efficacy in a mouse seizure model[133]. - The company aims to expand its platform across biopharmaceutical and healthcare markets while complying with healthcare data privacy regulations[137]. - Lunai Bioworks Inc. has undergone several name changes and acquisitions, with the latest being the acquisition of BioSymetrics in April 2025[141]. - The company plans to secure additional funding through equity or debt financing to support commercialization and development of its AI-driven cancer diagnostics platform[143].

Employment and Workforce - In fiscal 2025, Starbucks employed approximately 381,000 people worldwide, with about 223,000 in the U.S. and 158,000 outside the U.S.[32] - In fiscal 2025, more than 230,000 partners received a Bean Stock grant, giving them an ownership stake in Starbucks[28] - Starbucks aims to fill 90% of retail leadership roles internally, promoting career growth for hourly partners[28] - Starbucks covers 100% of tuition for a first-time online bachelor's degree from Arizona State University for partners working an average of 20 hours or more each week[28] - The company has committed to fair pay principles to ensure equitable compensation for all partners, regardless of race or gender[31] Revenue and Financial Performance - Revenues from reportable operating segments for fiscal 2025 were as follows: North America (74%), International (21%), and Channel Development (5%)[40] - Revenue from company-operated stores accounted for 83% of total net revenues during fiscal 2025[46] - Licensed stores generated 12% of total net revenues in fiscal 2025[51] - Consolidated net revenues increased 3% to $37.2 billion in fiscal 2025 compared to $36.2 billion in fiscal 2024, driven by new store openings and incremental revenue from the Global Coffee Alliance[171] - North America segment revenue increased 1% in fiscal 2025, primarily due to a net new company-operated store growth of 4%, or 441 stores, despite a 2% decline in comparable store sales[172] - International segment revenue increased 7% in fiscal 2025, driven by new store openings and the conversion of 113 licensed stores to company-operated stores following the acquisition of 23.5 Degrees Topco Limited[173] - Channel Development segment revenue increased 6% in fiscal 2025, primarily due to an increase in revenue in the Global Coffee Alliance[174] Store Operations and Expansion - Total company-operated stores reached 21,514 as of September 28, 2025, with a net increase of 496 stores during the fiscal year[48] - Total licensed stores reached 19,476 as of September 28, 2025, with a net increase of 295 stores during the fiscal year[53] - The North America segment includes 11,018 company-operated stores and 7,293 licensed stores, making up 52% and 48% of total stores, respectively[44] - The International segment includes 10,496 company-operated stores and 12,183 licensed stores, making up 46% and 54% of total stores, respectively[44] - The company plans to close underperforming stores in North America, with closures expected to be completed in the first half of fiscal 2026, which may reduce baseline revenues but improve operating margins[176] Strategic Initiatives - The "Back to Starbucks" strategy was announced in Q4 of fiscal 2024 to enhance customer experience and return to growth[18] - Strategic initiatives under the "Back to Starbucks" plan aim to improve service models, enhance customer experience, and expand digital engagement, but may incur significant additional costs and face execution challenges[74] - Starbucks is focused on empowering coffeehouse leaders and enhancing customer experience through the Green Apron Service model, which was implemented across the U.S. company-operated store portfolio[177] - A new strategic joint venture with Boyu Capital aims to accelerate long-term growth in China, emphasizing investments in store partners and enhancing the coffeehouse experience[177] Financial Challenges and Risks - Consolidated operating income decreased to $2.9 billion in fiscal 2025, with an operating margin of 7.9%, down from 15.0% in fiscal 2024, reflecting a contraction of 710 basis points[185] - Diluted earnings per share (EPS) declined to $1.63 in fiscal 2025 from $3.31 in fiscal 2024, primarily due to the contraction in operating margin[185] - The company anticipates macroeconomic challenges, including new tariffs and dynamic coffee prices, will continue but remains encouraged by the results from its "Back to Starbucks" initiatives[177] - The company faces risks in new store openings, including rising development costs and potential cannibalization of sales from existing locations, which could adversely affect operating results[85] - Health concerns regarding product ingredients and changing consumer preferences may lead to reduced demand and impact financial performance[80] - The company is subject to various risks related to brand value, including potential negative impacts from public perception, operational challenges, and macroeconomic volatility[69] Market and Competitive Environment - The specialty coffee market is highly competitive, with significant pressure from large quick-service competitors in the U.S. and established brands globally, potentially reducing profitability[114] - The international segment is critical for growth, with performance in key markets affecting overall consolidated results; economic downturns in these regions could materially impact financial outcomes[89] - The company operates in 89 global markets, facing diverse cultural, regulatory, geopolitical, and economic environments that could adversely affect financial performance[91] Supply Chain and Operational Risks - Starbucks operates ten farmer support centers to promote best practices in coffee production and ensure high-quality supply[59] - The company utilizes various purchasing strategies, including fixed-price and price-to-be-fixed commitments, to secure an adequate supply of quality green coffee[57] - The volatility in the availability and pricing of high-quality arabica coffee beans could significantly affect profitability, as coffee typically trades at a premium above the "C" commodity price[95][96] - Supply chain disruptions, including those caused by natural disasters or geopolitical conflicts, could materially impact the company's ability to deliver products and maintain profitability[101] - Labor costs are a significant concern, with potential increases due to new legislation and competitive pressures in the labor market, impacting overall operational costs[109] Compliance and Legal Risks - The evolving regulatory environment, including new corporate governance and public disclosure regulations, may increase compliance costs and expose the company to legal risks[118] - The company faces potential litigation related to various claims, including employment practices and data privacy, which could adversely affect financial performance and reputation[127] - Cybersecurity threats, including unauthorized access and data breaches, could result in significant financial costs and reputational harm[129] - Compliance with privacy and data protection laws is complex and evolving, with potential penalties for noncompliance that could impact operations and financial performance[130] Financial Position and Capital Management - Cash and investments totaled $3.7 billion as of September 28, 2025, down from $3.8 billion in the previous year, with approximately $1.6 billion held in foreign subsidiaries[208] - The company replaced its $3.0 billion unsecured five-year revolving credit facility with a new facility of the same amount, maturing on June 13, 2030[209][210] - Total available contractual borrowing capacity for general corporate purposes was $3.0 billion as of the end of fiscal 2025[213] - No borrowings were outstanding under the commercial paper program as of September 28, 2025, with a maximum aggregate amount of $3.0 billion available[214] - The company maintained compliance with all applicable covenants related to its credit facilities as of September 28, 2025[212]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41959 _________________________ SolarMax Technology, Inc. (Exact name of registrant as specified in its ch ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42451 TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. (Exact name of registrant as specified in its charter) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42451 TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. (Exact name of registrant as specified in its charter) ...

Bitcoin Mining Operations - The company entered the sustainable Bitcoin mining industry in 2024, acquiring three facilities with a total of 1,522 BITMAIN Antminer units, powered by sustainable energy [164][180]. - The average cost of Bitcoin mined is approximately $51,031, with Alberta generating 1 BTC every 59 days at a cost of $40,300, and Ohio generating 1 BTC every 19.6 days at a cost of $54,600 [193]. - The company has established a Bitcoin treasury strategy, holding up to 50% of mined assets, and has only sold three BTC to maintain operations [190]. - The company completed the acquisition of a Bitcoin mining facility in Alberta for $1.5 million and a facility in Ohio for $4.765 million, enhancing its commitment to sustainable energy solutions [186][187]. - The acquisition of the Redwater Bitcoin Mining Facility increased the Company's hash rate by over 600% [195]. - Revenue from bitcoin mining for the three months ended September 30, 2025, was $525,914, and for the nine months, it was $1,250,592, with the Company mining 4.7 BTC and 12.2 BTC respectively [207]. - The Company created new job opportunities in advanced technology and sustainable agriculture, addressing workforce development needs in Ohio [197]. Financial Performance - Total operating expenses for the three months ended September 30, 2025, decreased by $2.3 million, or 43%, compared to the same period in 2024 [210]. - Operating expenses for the nine months ended September 30, 2025, decreased by $0.8 million, or 8%, compared to the same period in 2024 [211]. - Net loss of $16,557,023 recorded for the nine months ended September 30, 2025, with an accumulated deficit of $77,339,142 [218]. - Net cash used in operating activities increased by $2,005,085, totaling $5,434,274 for the nine months ended September 30, 2025 [221]. - Net cash used in investing activities was $5,516,822, including $4,765,000 for the Bald Eagle Bitcoin Mining Acquisition [224]. - Net cash provided by financing activities was $11,465,126, primarily from net proceeds of debentures totaling $9,795,000 [225]. Expenses and Compensation - Share-based compensation increased by $1,074,556, or 1,691%, during the three months ended September 30, 2025 [210]. - Share-based compensation increased by $1,218,932, or 955%, due to compensation issued to the Board of Directors, CEO, and CFO [212]. - Wages and salaries increased by $427,109, or 35%, due to increased staffing for Bitcoin mining and corporate [212]. - Consulting expenses decreased by $137,719, or 42%, due to limited services obtained from outside consultants [212]. - Research and development expenses decreased by $13,688, or 269%, due to settlement and write-off of RCS related expenses [212]. - Total other expenses increased by $5,783,940, or 3,800%, for the three months ended September 30, 2025 compared to the same period in 2024 [213]. - Intangible asset impairment of $4,137,271 did not reoccur in the nine months ended September 30, 2025 [212]. Strategic Initiatives - The company’s UN(THINK)™ Awakened Flour™ product line has been developed, offering enhanced nutrition with over five times more fiber and up to two times more protein compared to conventional flour [177]. - The company has established supply chain logistics with warehouses in Canada and the US, and is in discussions with bakeries for product integration [169]. - The company’s modular architecture allows for cryptocurrency mining and tailored compute capabilities for AI and edge computing [168]. - The company is developing a plan to utilize waste heat from mining operations for aquaculture, aiming to produce shrimp and micro-greens [182][185]. - The Company plans to rely on exemptions provided by the JOBS Act, including delaying the adoption of certain accounting standards [204]. - The Company appointed Peter Wylie as Chief Operating Officer effective November 5, 2025, bringing significant operational financial experience [200]. - The Company is committed to enhancing food security in Ohio, where over 14% of households face food insecurity challenges [197].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-25844 TAITRON COMPONENTS INCORPORATED (Exact name of registrant as specified in its charter) | California | 95-424 ...

Financial Performance - Total revenue for Q3 2025 was $2,305,000, a 2.1% increase from $2,257,000 in Q3 2024[10] - Gross profit for Q3 2025 was $1,383,000, compared to $1,355,000 in Q3 2024, reflecting a gross margin improvement[10] - Net loss for Q3 2025 was $4,892,000, compared to a net loss of $3,547,000 in Q3 2024, representing an increase in losses[10] - For the nine months ended September 30, 2025, the company reported a net loss of $9,411,000, an improvement from a net loss of $11,706,000 for the same period in 2024, representing a 19.7% reduction in losses[14] - Product revenue for the three months ended September 30, 2025, was $2,305,000, a 2% increase from $2,257,000 in the same period in 2024[190] - Product revenue for the nine months ended September 30, 2025, was $6,988,000, a 2% increase from $6,833,000 in 2024[202]. Expenses and Cost Management - Operating expenses for Q3 2025 totaled $2,962,000, down from $5,099,000 in Q3 2024, indicating a significant reduction in costs[10] - Research and development expenses for Q3 2025 were $739,000, down from $908,000 in Q3 2024, indicating a focus on cost management[10] - Personnel costs for the three months ended September 30, 2025, were $1,635,000, down from $3,294,000 in the same period of 2024, showing a reduction of 50.5%[32] - Sales and marketing expenses for the three months ended September 30, 2025, decreased by $1,460,000, or 68%, compared to the same period in 2024[196]. - General and administrative expenses for the three months ended September 30, 2025, decreased by $508,000, or 25%, compared to the same period in 2024[197]. Cash and Assets - Cash and cash equivalents increased to $3,809,000 as of September 30, 2025, up from $1,769,000 at December 31, 2024[9] - Total assets rose to $7,296,000 as of September 30, 2025, compared to $5,491,000 at December 31, 2024[9] - Total liabilities increased to $11,640,000 as of September 30, 2025, up from $8,054,000 at December 31, 2024[9] - The accumulated deficit increased to $540,808,000 as of September 30, 2025, compared to $531,397,000 at December 31, 2024[9] Shareholder and Capital Management - The company issued 6,550,000 shares under a private placement offering, raising approximately $2,815,000 net of issuance costs[12] - The company plans to raise capital through equity offerings and may experience significant dilution for existing shareholders[20] - The company has outstanding warrants that may be exercised, although there is no assurance that they will be[19] Market and Product Development - The company’s operations are focused on developing and commercializing diagnostic tests for gynecologic disease, including the Ova1Plus workflow and OvaWatch[17] - The company plans to broaden its commercial focus from ovarian cancer to include differential diagnosis of other gynecological diseases, which is expected to enhance market opportunities[154] - The addressable market for the company's tests is projected to increase to between 2 and 4 million tests per year following the successful expansion of the OvaWatch test features[166] - The ENDOinform program aims to develop a multi-marker test for diagnosing endometriosis, targeting a market of over 6.5 million women in the U.S.[165] Operational Highlights - The number of OvaSuite tests performed decreased by 5% to 5,727 during the three months ended September 30, 2025, compared to 6,001 tests in the same period in 2024[191] - The company rebalanced its salesforce, resulting in a 167% increase in sales per full-time equivalent salesperson in Q3 2025 compared to Q3 2024[180] - OvaWatch was approved for sale in New York State, expanding the distribution agreement with BioReference to include this product[169] Regulatory and Compliance - The company’s common stock was delisted from Nasdaq on April 15, 2025, due to failure to meet the minimum stockholders' equity requirement[22] - The company has applied for an LCD for OvaWatch, which is currently under review, to enhance reimbursement coverage[173] Future Outlook - The company expects to continue incurring net losses and negative cash flows from operations for the remainder of 2025[18] - The company is evaluating the potential impact of ASU 2023-09, which addresses income tax disclosures, effective for fiscal years beginning after December 15, 2024[43]